Explore the Potential with AI-Driven Innovation
The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.
From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.
In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.
We utilise our cutting-edge, exclusive workflow to develop focused libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our methodology leverages molecular simulations to examine a vast array of proteins, capturing their dynamics in both isolated forms and in complexes with other proteins. Through ensemble virtual screening, we thoroughly account for the protein's conformational mobility, identifying critical binding sites within functional regions and distant allosteric locations. This detailed exploration ensures that we comprehensively assess every possible mechanism of action, with the objective of identifying novel therapeutic targets and lead compounds that span a wide spectrum of biological functions.
Our library distinguishes itself through several key aspects:
partner
Reaxense
upacc
P62266
UPID:
RS23_HUMAN
Alternative names:
40S ribosomal protein S23
Alternative UPACC:
P62266; P39028; Q6IB08
Background:
Small ribosomal subunit protein uS12, also known as 40S ribosomal protein S23, is a pivotal component of the ribosome, essential for protein synthesis. It plays a crucial role in the assembly of the small ribosomal subunit, mRNA binding, and translational accuracy, ensuring the correct amino acids are polymerized into polypeptide chains.
Therapeutic significance:
The protein's involvement in Brachycephaly, trichomegaly, and developmental delay highlights its potential as a therapeutic target. Understanding the role of Small ribosomal subunit protein uS12 could open doors to potential therapeutic strategies for treating this developmental disorder.